vs
威伯科（CVGI）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是威伯科的1.4倍（$219.9M vs $154.8M），Orthofix Medical Inc.同比增速更快（2.0% vs -5.2%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $8.7M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -10.8%）
威伯科控股曾是总部位于美国的重型商用车零部件供应商，主打电子制动、稳定性控制、悬挂及传动自动化系统，产品广泛应用于卡车、巴士、挂车以及非道路作业车辆等各类商用车领域，是商用车行业重要的零部件提供商。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CVGI vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$154.8M
营收增速更快
OFIX
高出7.2%
-5.2%
自由现金流更多
OFIX
多$8.1M
$8.7M
两年增速更快
OFIX
近两年复合增速
-10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $154.8M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 9.7% | 71.1% |
| 营业利润率 | -1.2% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | -5.2% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVGIOFIX
| Q4 25 | $154.8M | $219.9M | ||
| Q3 25 | $152.5M | $205.6M | ||
| Q2 25 | $172.0M | $203.1M | ||
| Q1 25 | $169.8M | $193.6M | ||
| Q4 24 | $163.3M | $215.7M | ||
| Q3 24 | $171.8M | $196.6M | ||
| Q2 24 | $193.7M | $198.6M | ||
| Q1 24 | $194.6M | $188.6M |
净利润CVGIOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-7.1M | $-22.8M | ||
| Q2 25 | $-4.8M | $-14.1M | ||
| Q1 25 | $-4.3M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $9.5M | $-27.4M | ||
| Q2 24 | $-1.6M | $-33.4M | ||
| Q1 24 | $2.9M | $-36.0M |
毛利率CVGIOFIX
| Q4 25 | 9.7% | 71.1% | ||
| Q3 25 | 10.5% | 72.2% | ||
| Q2 25 | 11.4% | 68.7% | ||
| Q1 25 | 10.5% | 62.8% | ||
| Q4 24 | 8.0% | 69.0% | ||
| Q3 24 | 9.6% | 68.7% | ||
| Q2 24 | 10.6% | 67.8% | ||
| Q1 24 | 11.9% | 67.5% |
营业利润率CVGIOFIX
| Q4 25 | -1.2% | 0.2% | ||
| Q3 25 | -0.7% | -8.3% | ||
| Q2 25 | 0.5% | -7.9% | ||
| Q1 25 | 0.8% | -25.2% | ||
| Q4 24 | -3.2% | -5.3% | ||
| Q3 24 | -0.6% | -9.6% | ||
| Q2 24 | 0.5% | -12.5% | ||
| Q1 24 | 2.3% | -15.6% |
净利率CVGIOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -4.6% | -11.1% | ||
| Q2 25 | -2.8% | -6.9% | ||
| Q1 25 | -2.5% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 5.5% | -13.9% | ||
| Q2 24 | -0.8% | -16.8% | ||
| Q1 24 | 1.5% | -19.1% |
每股收益（稀释后）CVGIOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | $-0.05 | $-0.88 | ||
| Q1 24 | $0.09 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $104.9M | — |
| 股东权益账面价值 | $133.4M | $450.0M |
| 总资产 | $391.7M | $850.6M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CVGIOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务CVGIOFIX
| Q4 25 | $104.9M | — | ||
| Q3 25 | $108.2M | $157.2M | ||
| Q2 25 | $118.2M | $157.0M | ||
| Q1 25 | $117.4M | $156.9M | ||
| Q4 24 | $135.5M | $157.0M | ||
| Q3 24 | $128.8M | $118.5M | ||
| Q2 24 | $142.0M | $118.0M | ||
| Q1 24 | $155.7M | $118.2M |
股东权益CVGIOFIX
| Q4 25 | $133.4M | $450.0M | ||
| Q3 25 | $136.5M | $442.5M | ||
| Q2 25 | $142.6M | $458.3M | ||
| Q1 25 | $136.7M | $458.3M | ||
| Q4 24 | $135.6M | $503.1M | ||
| Q3 24 | $179.3M | $525.9M | ||
| Q2 24 | $169.6M | $546.0M | ||
| Q1 24 | $175.5M | $570.3M |
总资产CVGIOFIX
| Q4 25 | $391.7M | $850.6M | ||
| Q3 25 | $400.3M | $832.6M | ||
| Q2 25 | $429.8M | $837.2M | ||
| Q1 25 | $419.8M | $823.1M | ||
| Q4 24 | $424.6M | $893.3M | ||
| Q3 24 | $495.3M | $867.9M | ||
| Q2 24 | $503.2M | $882.0M | ||
| Q1 24 | $509.2M | $906.0M |
负债/权益比CVGIOFIX
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.79× | 0.36× | ||
| Q2 25 | 0.83× | 0.34× | ||
| Q1 25 | 0.86× | 0.34× | ||
| Q4 24 | 1.00× | 0.31× | ||
| Q3 24 | 0.72× | 0.23× | ||
| Q2 24 | 0.84× | 0.22× | ||
| Q1 24 | 0.89× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $8.7M | $16.8M |
| 自由现金流率自由现金流/营收 | 5.6% | 7.6% |
| 资本支出强度资本支出/营收 | 2.3% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $34.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CVGIOFIX
| Q4 25 | $12.3M | $27.7M | ||
| Q3 25 | $-1.7M | $12.4M | ||
| Q2 25 | $18.9M | $11.6M | ||
| Q1 25 | $15.2M | $-18.4M | ||
| Q4 24 | $-26.6M | $23.7M | ||
| Q3 24 | $-17.1M | $11.7M | ||
| Q2 24 | $12.6M | $9.0M | ||
| Q1 24 | $-2.4M | $-18.6M |
自由现金流CVGIOFIX
| Q4 25 | $8.7M | $16.8M | ||
| Q3 25 | $-3.5M | $2.5M | ||
| Q2 25 | $17.4M | $4.5M | ||
| Q1 25 | $11.4M | $-25.1M | ||
| Q4 24 | $-30.6M | $15.2M | ||
| Q3 24 | $-20.3M | $6.3M | ||
| Q2 24 | $6.4M | $-360.0K | ||
| Q1 24 | $-7.4M | $-29.1M |
自由现金流率CVGIOFIX
| Q4 25 | 5.6% | 7.6% | ||
| Q3 25 | -2.3% | 1.2% | ||
| Q2 25 | 10.1% | 2.2% | ||
| Q1 25 | 6.7% | -13.0% | ||
| Q4 24 | -18.7% | 7.0% | ||
| Q3 24 | -11.8% | 3.2% | ||
| Q2 24 | 3.3% | -0.2% | ||
| Q1 24 | -3.8% | -15.4% |
资本支出强度CVGIOFIX
| Q4 25 | 2.3% | 4.9% | ||
| Q3 25 | 1.2% | 4.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 2.2% | 3.5% | ||
| Q4 24 | 2.4% | 4.0% | ||
| Q3 24 | 1.9% | 2.7% | ||
| Q2 24 | 3.2% | 4.7% | ||
| Q1 24 | 2.6% | 5.6% |
现金转化率CVGIOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.79× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.80× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
